Myocardial Infarction—From Atherosclerosis to Thrombosis: Uncovering New Diagnostic and Therapeutic Approaches
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
yocardial infarction (MI) is a leading cause of death and disability in the developed world and a major socioeconomic burden. 1 It is typically the culmination of a long and complex process where the formation of an occlusive thrombus within a coronary artery leads to cardiac ischemia and infarction.Atherosclerosis-the primary underlying disease process-begins in early adulthood and is driven by lipid accumulation in the arterial wall, inflammation, and vascular injury.As it progresses, some plaques evolve to take on a more unstable phenotype with greater degrees of inflammation.Eventually, plaque rupture can occur, and contact of blood with the exposed subendothelial matrix and plaque content causes the formation of occlusive thrombi.This cascade of events leads to the clinical manifestation of MI with angina pectoris, myocyte death, and ultimately, impaired cardiac function.Other coronary artery pathologies such as plaque erosion or spontaneous coronary artery dissection can also cause MI, although their frequency compared with plaque rupture is unclear and controversial, mainly based on a surprisingly low number of autopsy studies available.Preventing and treating MI faces several challenges, and there is the need for thorough research and hopefully breakthroughs in several areas.This includes research on the mechanisms driving plaque instability and causing MI, identification of the patient at risk of MI, identification of plaques that are vulnerable, developing approaches for plaque stabilization, and finally if MI occurs, the treatment/prevention of thrombotic occlusions, as well as preventing ischemia/reperfusion (I/R) injury.This highlight article shines light on recent high-quality articles published in Arteriosclerosis, Thrombosis, and Vascular Biology and illustrates the groundbreaking work taking place in these areas of research and the promise it holds for patients in preventing or treating MI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx393 · Cited by 9,728
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
Benjamin, E. J., Muntner, P., Alonso, A., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Das, S. R., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000659 · Cited by 9,036
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Ridker, P. M., Hennekens, C. H., Buring, J. E., & Rifai, N. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003233421202 · Cited by 5,850
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P., & Hennekens, C. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361401 · Cited by 5,504
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Cited by
Wnt signaling pathways in biology and disease: mechanisms and therapeutic advances
Xue, C., Chu, Q., Shi, Q., Zeng, Y., Lu, J., & Li, L. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02142-w · Cited by 281
Ren, F., Huang, J., Dai, T., & Gan, F. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-21-525 · Cited by 8
Metadata
- Authors
- Palasubramaniam, J., Wang, X., & Peter, K.
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 2019-08
- Volume
- 39
- Issue
- 8
- Pages
- e176-e185
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- OpenAlex
- W2969719524
- Cited by
- 192
- References
- 22
- FWCI
- 10.76
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Myocardial Infarction—From Atherosclerosis to Thrombosis: Uncovering New Diagnostic and Therapeutic Approaches. https://app.cochat.ai/papers/10.1161/atvbaha.119.312578
- The paper
- Palasubramaniam, J., Wang, X., & Peter, K. (2019). Myocardial Infarction—From Atherosclerosis to Thrombosis: Uncovering New Diagnostic and Therapeutic Approaches. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/atvbaha.119.312578
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.